Answers are grounded in this paper and cite their sources.
Metabolic syndrome is a clinically recognized group of concurrent physiological dis-orders. They include insulin resistance, high blood pressure, dyslipidemia, and obesity. These conditions interact synergistically, enhancing the pathological effect of each other. It significantly increases the risk of developing autoimmune disorders and the development of malignant tumors. Emerging evidence has positioned the gut micro-biome as a pivotal determinant of systemic health. Disruption of this microbial eco-system (bacterial imbalance) has been mechanically linked to many disease conditions. This review critically evaluates the therapeutic efficacy of prebiotics, probiotics, and synbiotics in the management of metabolic syndrome. These interventions share a common ability to target gut microorganisms as a modifiable therapeutic axis. To cap-ture an unlimited amount of research on this topic. This review analyzes the mecha-nisms of action of probiotics, prebiotics, and synbiotics, linking them to metabolic syndrome and associated diseases, their functional benefits, and their association with nutrition. These effects also target the primary pathways for managing metabolic syn-drome. However, the large variability between existing studies limits reaching defini-tive conclusions. Standardized and carefully designed clinical trials remain essential for future research.
No takes yet. Share an insight, caveat, or question.
Musa et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: